Gallium-68 NOTA AE105

Drug Profile

Gallium-68 NOTA AE105

Alternative Names: 68Ga NOTA AE105; 68Ga-NOTA-Asp-Cha-Phe-Ser-Arg-Tyr-Leu-Trp-Ser; CS 001

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Curasight
  • Developer Curasight; Rigshospitalet
  • Class Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oropharyngeal cancer; Prostate cancer

Most Recent Events

  • 19 Oct 2016 Phase-II clinical trials in Head and neck cancer (Diagnosis) in Denmark (IV) (EudraCT2016-002082-65)
  • 30 Aug 2016 Phase-II clinical trials in Glioblastoma (Diagnosis) in Denmark (IV) (EudraCT2016-002417-21)
  • 30 Aug 2016 Phase-II clinical trials in Prostate cancer (Diagnosis) in Denmark (IV) (EudraCT2016-002184-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top